Matinas BioPharma CFO Keith Kucinski resigns; CEO Jerome Jabbour named interim CFO

Matinas BioPharma Holdings, Inc.

Keith Kucinski resigned as CFO effective January 17, 2026, to pursue other opportunities.
Board appointed CEO and Chairman Jerome D. Jabbour as interim CFO effective January 22, 2026.
Jabbour retains roles as Chairman, President, and CEO; assumes principal financial and accounting officer duties.
No change in Jabbour's compensation or other material terms in connection with appointment.
No family relationships or transactions between Jabbour and any director or officer requiring disclosure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.